
A
200
$10^0$
$10^2$
$10^4$
W6/32
C
200
$10^0$
$10^2$
$10^4$
ICAM-1
B
200
$10^0$
$10^2$
$10^4$
CD29
D
200
$10^0$
$10^2$
$10^4$
LFA-3

FIGURE 1




FIG. 2

Table 1: Transplantation outcome of masking of donor human xenografts with HLA class I (W6/32) or CD29 antibodies or F(ab')$_2$ fragments prior to grafting

| Groups | Islet Tissue Treatment● | Days S/P Transplantation* | ACCEPTED/TOTAL+ |
|---|---|---|---|
| 1 | W6/32 F(ab')$_2$ | 30 days | 5/5 |
| 2 | W6/32 F(ab')$_2$ | 200 days | 5/5 |
| 3 | W6/32 Antibody | 30 days | 0/5 |
| 4 | W6/32 Antibody | 200 days | 0/5 |
| 5 | CD29 F(ab')$_2$ | 30 days | 0/5 |
| 6 | CD29 F(ab')$_2$ | 200 days | 0/5 |
| 7 | CD29 Antibody | 30 days | 0/5 |
| 8 | CD29 Antibody | 200 days | 0/5 |
| 9 | W6/32 F(ab')$_2$+CD29 F(ab')$_2$ | 30 days | 5/5 |
| 10 | W6/32 F(ab')$_2$+CD29 F(ab')$_2$ | 200 days | 5/5 |
| 11 | None | 30 days | 0/5 |
| 12 | None | 200 days | 0/5 |

* Days s/p transplantation represents the number of days after transplantation when BALB/c recipients of donor human islets were sacrificed.
● Clean human islet preparations express class I antigens but lack CD29 determinants
+ This ratio represents the number of successful transplants to the number of transplants performed. Islet xenograft survival was evaluated with hematoxylin and eosin staining for the evaluation of lymphocyte infiltrates and aldehyde-fuschin staining for the detection of beta cells. Aldehyde-fuchin stains well granulated beta cells purple: hematoxylin and eosin stains lymphocytes black. Accepted in this manuscript represents easily located well granulated islets under the kidney capsule lacking lymphocyte foci. Rejction in this manuscript represents a transplant site with large lymphocyte accumulations and/or subcapsular fibrosis without islets.

TABLE 2: Function of Human Islet Xenografts Evaluated by Human C' Peptide Levels




Group 1 W6/32 F(ab')2, d30
Group 2 W6/32 F(ab')2, d200
Group 3 W6/32 Antibocy, d30
Group 4 W6/32 Antibody, d200
Group 5 CD29 F(ab')2, d30
Group 6 CD29 F(ab')2, d 200
Group 7 CD29 Antibody, d30
Group 8 CD29 Antibody, d200
Group 9 W6/32+CD29 F(ab')2, d30
Group 10 W6/32 + CD29 F(ab')2, d200
Group 11 No treatment, d30
Group 12 No treatment, d200

TABLE 3 Transplantation of RIN insulinoma cells into nonimmunosuppressed BABL/c recipients.

| DONOR RIN TREATMENT | HISTOLOGIC RESULTS AT AUTOPSY |
|---|---|
| None | All 4 mice lack RIN cells at 1, 2, 3, and 4 months with the transplant site demonstrating subcapsular fibrosis. |
| Anti-RIN Antibody | All 4 mice lack RIN cells at 1, 2, 3, and 4 months with the transplant site demonstrating subcapsular fibrosis. |
| Anti-RIN F(ab')2 fragments | All 4 mice demonstrate RIN cell survival at serial autopsy times of 1, 2, 3, and 4 months after transplantation. Slight but consistent lymphocytic infiltrates are visible at the transplant site |